carbapenem-resistant Acinetobacter
Jump to navigation
Jump to search
Epidemiology
- carbapenem-resistant Acinetobacter fastest increasing etiology of nosocomial pneumonia 2019-2020[1]
Pathology
Laboratory
Management
- Carbapenem-resistant Acinetobacter baumannii
- durlobactam sulbactam in combination with meropenem or imipenem-cilastatin[2]
More general terms
Additional terms
References
- ↑ 1.0 1.1 Rapid Review Quiz: Hospital-Acquired Pneumonia Medscape. Sept 15, 2022 https://reference.medscape.com/viewarticle/980567
- ↑ 2.0 2.1 Tamma PD, Heil EL, Justo JA, Mathers AJ, Satlin MJ, Bonomo RA. Infectious Diseases Society of America 2024 Guidance on the Treatment of Antimicrobial-Resistant Gram-Negative Infections. Clin Infect Dis. 2024 Aug 7:ciae403. PMID: https://www.ncbi.nlm.nih.gov/pubmed/39108079 https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciae403/7728556